Addyi (Flibanserin) Missed-Dose Protocol: What to Do and When to Resume

Why Bedtime Dosing Is Non-Negotiable

Flibanserin must be taken at bedtime because it causes dose-dependent drops in blood pressure and central nervous system depression. The FDA-approved prescribing information specifies bedtime administration to reduce the risk of hypotension, syncope, and accidental injury during waking hours [1]. This is not a soft recommendation.

In pre-approval clinical pharmacology studies, subjects who took flibanserin during daytime hours experienced significantly higher rates of symptomatic hypotension compared to those dosed at bedtime [1]. The drug's sedative properties compound this risk. Blood pressure can drop within 1 to 2 hours of ingestion, and the effect is amplified when the patient is upright and active. Taking a missed dose in the morning or afternoon bypasses the protective window that sleep provides.

The Addyi REMS (Risk Evaluation and Mitigation Strategy) program exists specifically because of these hemodynamic effects. Both prescribers and pharmacies must be certified before dispensing flibanserin [2]. The REMS documentation reinforces that bedtime-only dosing is a safety requirement, not a convenience suggestion. Dr. Janet Woodcock, then-Director of the FDA's Center for Drug Evaluation and Research, stated during the 2015 approval proceedings: "The approval of Addyi provides women distressed by their low sexual desire with an approved treatment option" while noting that the REMS was necessary to "mitigate the risk of severe hypotension and syncope" [2].

Exact Steps When You Miss a Dose

The protocol is simple: skip it. Resume your regular 100 mg dose the following night at bedtime. Do not take two tablets to compensate.

This instruction comes directly from the FDA label, which states: "If a dose is missed at bedtime, the patient should be advised to take the next dose at bedtime the following day" and to "not double the next dose" [1]. There is no clinical scenario in which catching up on a missed flibanserin dose is appropriate.

The reasoning is pharmacokinetic. Flibanserin has a terminal half-life of approximately 11 hours [1]. A single missed dose clears the therapeutic window within roughly two half-lives. Doubling the dose the next evening would produce supratherapeutic plasma levels, increasing the probability of syncope by a magnitude that the clinical trials were not designed to test. In the BEGONIA trial (N=1,175), adverse events including dizziness (11.4% vs. 2.3% placebo), somnolence (11.4% vs. 3.3%), and nausea (10.4% vs. 3.6%) were already clinically significant at the standard 100 mg bedtime dose [3].

A practical framework for handling missed doses:

1. Realized before falling asleep the same night: Take the dose immediately (you are still within the bedtime window).
2. Realized the next morning or during the day: Skip it. Do not take it.
3. Missed two or more consecutive nights: Resume at the standard 100 mg dose the next bedtime. Do not stack doses.
4. Unsure whether you took it: Skip the dose to err on the side of avoiding a double dose.

How Missed Doses Affect Flibanserin's Efficacy

Flibanserin is not an on-demand medication. It works through gradual neurochemical modulation, and sporadic dosing undermines this process.

Unlike sildenafil or tadalafil (which act on peripheral vasculature within 30 to 60 minutes), flibanserin targets central serotonin and dopamine pathways [4]. It functions as a serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist, with secondary effects on dopaminergic activity in the prefrontal cortex [4]. These neuroadaptive changes require sustained receptor occupancy over weeks.

The FDA label explicitly instructs prescribers to "discontinue flibanserin after 8 weeks if the patient does not report an improvement in symptoms" [1]. This 8-week benchmark assumes consistent daily dosing. Frequent missed doses extend the timeline to steady-state pharmacodynamics or may prevent it from being reached at all.

In the pooled phase III data (VIOLET, DAISY, and BEGONIA), the mean increase in satisfying sexual events was 0.5 to 1.0 per month above placebo, with statistically significant improvements in desire scores on the Female Sexual Function Index (FSFI) [3][5]. These modest but measurable gains depended on protocol-adherent daily dosing. Post-hoc analyses of trial participants with lower adherence showed attenuated treatment effects, though the data were not powered to quantify an exact dose-response for intermittent use.

Flibanserin's Mechanism and Why Consistency Matters

Flibanserin corrects a serotonin-dopamine imbalance hypothesized to suppress sexual desire. This correction is not instant.

The drug was originally developed as an antidepressant. During early trials, researchers observed that it increased sexual desire in female participants without significant antidepressant effects [4]. The proposed mechanism involves reducing excessive serotonergic inhibition of dopamine and norepinephrine release in the medial prefrontal cortex [4]. By blocking 5-HT2A receptors and activating 5-HT1A autoreceptors, flibanserin shifts the balance toward dopaminergic and noradrenergic tone.

Dr. Anita Clayton, a principal investigator on multiple flibanserin trials and Professor of Psychiatry at the University of Virginia, described the pharmacology: "Flibanserin appears to work by decreasing serotonin and increasing dopamine and norepinephrine in specific brain regions involved in the sexual response" [5].

This neurochemical recalibration follows a time course similar to SSRIs and SNRIs, where receptor downregulation and second-messenger cascade changes take 2 to 4 weeks to stabilize. Missing doses disrupts receptor occupancy at 5-HT1A and 5-HT2A sites, potentially resetting the adaptation clock. A patient who misses one dose in a month is unlikely to notice a clinical difference. A patient who misses doses several times per week may never achieve the steady-state receptor modulation that the drug requires to work.

The Alcohol Interaction: Amplified Risk After Missed Doses

Alcohol and flibanserin together can cause dangerous hypotension and loss of consciousness. This risk does not disappear on days you skip a dose, but the timing dynamics change.

The FDA required a boxed warning about concomitant alcohol use [1]. In a dedicated interaction study, 25% of subjects who combined flibanserin with alcohol (0.4 g/kg, equivalent to roughly two drinks) experienced clinically significant hypotension or syncope requiring intervention, compared to 0% with flibanserin or alcohol alone [1][2].

The REMS requires patients to abstain from alcohol for at least 2 hours before and after taking flibanserin [2]. On a night when a dose is skipped, the patient is not actively exposed to the drug's acute hemodynamic effects, because the prior dose's plasma concentration has dropped below the threshold (half-life of ~11 hours). This does not mean alcohol is safe in unlimited quantities. Patients should follow their prescriber's general alcohol guidance, and the interaction concern fully re-applies the next evening when dosing resumes.

A common clinical pitfall: a patient misses her bedtime dose, drinks alcohol the following evening, and then takes flibanserin at that night's bedtime with residual alcohol still being metabolized. The FDA label warns against this exact sequence [1]. Patients should ensure at least 2 hours between their last alcoholic drink and their flibanserin dose, regardless of whether the previous night's dose was taken or missed.

CYP3A4 Inhibitors and Missed-Dose Timing

Patients taking moderate or strong CYP3A4 inhibitors face higher flibanserin plasma levels and greater risk if dosing errors occur.

Flibanserin is extensively metabolized by CYP3A4 [1]. Concomitant use of strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, certain HIV protease inhibitors) is contraindicated because they increase flibanserin AUC by approximately 4.5-fold [1]. Even moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, grapefruit juice in large quantities) can increase exposure 2-fold.

If a patient on a moderate CYP3A4 inhibitor accidentally doubles her flibanserin dose, the effective exposure could reach 4 times normal. This dramatically raises the syncope risk. For patients on any CYP3A4 inhibitor, strict adherence to the skip-and-resume protocol is especially important.

Prescribers should review the full medication list before initiating flibanserin and at every refill. Herbal supplements containing goldenseal or grapefruit-derived compounds can also inhibit CYP3A4 and should be flagged during medication reconciliation [1].

When to Reassess: The 8-Week Decision Point

The FDA sets a clear checkpoint. If flibanserin has not improved desire after 8 weeks of consistent nightly dosing, it should be discontinued.

This guidance is based on the phase III trial timelines. In the BEGONIA trial, separation from placebo on the desire domain of the FSFI became statistically significant by week 4, with maximum effect observed around weeks 8 to 12 [3]. The pooled responder analysis from VIOLET, DAISY, and BEGONIA showed that approximately 46% to 60% of flibanserin-treated patients reported meaningful improvement compared to 34% to 38% on placebo [5][6].

A clinician evaluating a patient at the 8-week mark should account for adherence. If the patient has missed more than 25% of doses, the 8-week window may not reflect a true therapeutic trial. In that scenario, a conversation about barriers to adherence (side effects, forgetfulness, bedtime routine disruption) should precede the decision to stop the medication. Pill organizers and phone alarms set 30 minutes before the patient's typical bedtime are the two most practical adherence tools for a once-daily bedtime medication.

Restarting After a Prolonged Gap

Patients who stop flibanserin for more than a few days and wish to restart do not need a dose titration. The approved dose is 100 mg at bedtime from day one.

Unlike certain psychiatric medications that require slow uptitration after a washout period, flibanserin's labeling does not specify a re-initiation protocol [1]. The 100 mg dose was the only effective dose studied in phase III trials. The 50 mg dose was tested in earlier studies and found insufficiently effective, while the 100 mg twice-daily dose produced unacceptable rates of somnolence and dizziness [6].

Patients restarting should be reminded of three things. First, the alcohol restriction applies from the first resumed dose. Second, the drug will again take at least 4 weeks of consistent dosing before effects on desire are expected. Third, the REMS requirements (including the patient-provider agreement) remain in effect for the duration of treatment [2]. If a patient discontinued because of side effects and is reconsidering, her prescriber should revisit whether those side effects (most commonly dizziness, somnolence, or nausea) are tolerable given the expected timeline to benefit.

Patients restarting flibanserin after a gap of more than 30 days should have their CYP3A4 inhibitor status reassessed, since new medications or supplements may have been added during the interval.